BCX9930 | Aplastic Anemia & MDS International Foundation Return to top.

BCX9930

Bone Marrow Disease(s): 
  • paroxysmal nocturnal hemoglobinuria (PNH)

BCX9930 is an oral small molecule inhibitor of Factor D currently in Phase 1 clinical development for the treatment of complement-mediated diseases.

Related Clinical Trials

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Share with addtoany.com.